AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19062112
Drug: Normal Sodium
RxNorm normalized name: sulfacetamide sodium Medicated Pad [Rosula NS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Sodium Intake (NSI) - 80 mmol/day of oral sodium supplements
Trial: 8378155
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine at a dose of 6 mg/kg
Trial: 8378155
Drug: Oral meperidine/promethazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral meperidine/promethazine combination at doses of 2 mg/kg and 0.5 mg/kg respectively
Trial: 8931526
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments combined
Trial: 26771908
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) and aspirin
Trial: 30344063
Drug: Aspirin only
RxNorm normalized name: Aspirin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin only
Trial: 23786503
Drug: Topical 4%
RxNorm normalized name: menthol topical 4% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 4% nicotinamide
Trial: 21955937
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg extended-release niacin for 4 weeks, then 1000 mg extended-release niacin for 4 weeks
Trial: 7641719
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia with 4% lignocaine
Trial: 31226187
Drug: Computer-assisted implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted implant planning and template-guided implant placement (CAIPP)
Trial: 29121061
Drug: Chloroquine 2500
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine 2500 mg total dose (1500 mg chloroquine base) over 3 days plus primaquine 15 mg daily for 14 days
Trial: 29121061
Drug: Tafenoquine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 400 mg once daily for 3 days
Trial: 25803763
Drug: Medication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication therapy management reconciliation service (MRS)
Trial: 19000538
Drug: Azelnidipine 8
RxNorm normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelnidipine 8 mg/day
Trial: 21471671
Drug: Azelnidipine 16
RxNorm normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelnidipine 16 mg/day
Trial: 16838827
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg to 40 mg daily plus IPT 1 session weekly
Trial: 16838827
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg to 40 mg daily
Trial: 12636462
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) plus exercise (n = 266)
Trial: 12636462
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) alone (n = 286)
Trial: 12636462
Drug: Exercise alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise alone or in combination with CBT
Trial: 8217759
Drug: Naftifine (Exoderil)
DrugBank: Naftifine (DB00735)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naftifine (Exoderil) applied twice daily for 4 weeks
Trial: 8217759
Drug: 1% clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clotrimazole plus 1% hydrocortisone (CHC; Canesten HC) applied twice daily for 4 weeks
Trial: 6641092
Drug: Alinidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine (40 mg three times a day)
Trial: 3330524
Drug: Propranolol and
RxNorm normalized name: propranolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol and atropine (0.2 mg kg‐1 and 0.04 mg kg‐1 respectively)
Trial: 31996370
Drug: PSA 1.01-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA 1.01-2.5 ng/mL
Trial: 31996370
Drug: PSA ≤
RxNorm normalized name: Prostate-Specific Antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA ≤ 0.5 ng/mL, aged ≥65 years
Trial: 16143120
Drug: Certolizumab 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certolizumab 400 mg
Trial: 26718934
Drug: Ammonia inhalation
RxNorm normalized name: ammonia INHALATION SPIRIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ammonia inhalation
Trial: 17689192
Drug: Hypnosis (highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis (highly hypnotic susceptible patients)
Trial: 2893635
Drug: Atenolol 25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 25, 50 and 100 mg
Trial: 2893635
Drug: Koe 3290
RxNorm normalized name: Koelers grass pollen extract
DrugBank: Koeleria macrantha pollen (DB10949)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Koe 3290 12.5, 25, 50 and 100 mg
Trial: 25551814
Drug: Thoracic paravertebral
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic paravertebral block with 150 mg levobupivacaine
Trial: 22038338
Drug: Internet training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet training (behaviorally focused and video-based training, 2 weekly visits)
Trial: 18950331
Drug: Caudal blockade
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal blockade with levobupivacaine 0.25% 2 mg x kg(‐1)
Trial: 16022917
Drug: Vinorelbine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 30 mg/m² with Carboplatin (VC)
Trial: 16022917
Drug: Vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m² with Gemcitabine (VG)
Trial: 18442449
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (FFNS) 110 microg once daily
Trial: 10505557
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin plus intermittent IP vancomycin
Trial: 8089288
Drug: Interferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2a (3 MU subcutaneously three times per week, increased to 12 MU, total dose of 216 MU over 2 months)
Trial: 57444
Drug: Fractionated insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fractionated insulin preparations (Nordisk Insulin Ltd)
Trial: 30506579
Drug: KCl infusion
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KCl infusion in quiescent muscle
Trial: 28984822
Drug: Walnut-enriched diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut-enriched diet (43 g walnuts/day)
Trial: 26039534
Drug: Candesartan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan treatment for 7 days, lowering blood pressure by 5/2 mmHg from day 2 onwards.
Trial: 23672632
Drug: placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo added to metformin and sulphonylurea
Trial: 18569468
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin (Enoxaparin sodium 0.2 ml, 20 mg, once daily subcutaneously)
Trial: 18569468
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (folic acid tablets 0.5 mg daily until 13 weeks gestation)
Trial: 17127550
Drug: Adrenergic blockers
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenergic blockers
Trial: 14679156
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily tobramycin (n = 29)
Trial: 11313659
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid - 300 mg/day for 28 days
Trial: 11313659
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - twice a day for 28 days
Trial: 1610866
Drug: OKT3, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3, 5 mg/day for 7 days
Trial: 1610866
Drug: ALG, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALG, 15 mg/kg/day for 7 days
Trial: 20934559
Drug: Darapladib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darapladib (160 mg enteric-coated tablets)
Trial: 7789626
Drug: Insulin-modified frequently
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-modified frequently sampled intravenous glucose tolerance test (FSIVGTT)
Trial: 2192563
Drug: Fluoxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (60 mg/day) plus behavior modification
Trial: 14722148
Drug: DSEC (dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSEC (dietary supplement containing ephedra [12 mg] and caffeine [40 mg])
Trial: 15457926
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei DN114001 fermented milk (10(8)-10(10) ufc/g), 3 cups per day for 8 weeks
Trial: 9777137
Drug: Hirudin treatment
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudin treatment in patients with ST elevation receiving thrombolytic therapy (TIMI 9)
Trial: 9777137
Drug: Hirudin treatment
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudin treatment in the full spectrum of acute coronary syndromes (GUSTO 2)
Trial: 7932515
Drug: Misoprostol 400
RxNorm normalized name: Misoprostol 400 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 400 micrograms oral dose
Trial: 2892768
Drug: Nizatidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine (300 mg 'nocte')
Trial: 2892768
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg 'nocte')
Trial: 27302544
Drug: Telephone-based cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based cognitive-behavioural therapy
Trial: 22978615
Drug: Diamel (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamel (two capsules before each of the three main meals daily for 1 year)
Trial: 22978615
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two capsules before each of the three main meals daily for 1 year)
Trial: 11905457
Drug: Minimum therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimum therapy at presentation plus maximum therapy at local relapse
Trial: 9654538
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg once daily, subcutaneously for not less than seven days)
Trial: 189385
Drug: Terbutaline 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 0.25 mg
Trial: 26665978
Drug: EOB body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EOB body cream
Trial: 21807659
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g dark chocolate (>85% cocoa)
Trial: 19494810
Drug: Atorvastatin (20‐80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20‐80 mg) before and after gastric bypass surgery
Trial: 11008908
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg per day
Trial: 8270392
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of cefuroxime (1.5 g i.v. on call to surgery)
Trial: 25102877
Drug: Aspirin continuation
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin continuation (100mg/d)
Trial: 25102877
Drug: Aspirin withdrawal
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin withdrawal 3 days pre-extraction
Trial: 25102877
Drug: Aspirin withdrawal
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin withdrawal 5 days pre-extraction
Trial: 22018760
Drug: Dolutegravir (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (all doses combined)
Trial: 10624993
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine 0.15 mg/kg after induction and normal saline at the end of surgery (PRE group)
Trial: 9098871
Drug: 0.12% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% betamethasone 17-valerate cream formulation
Trial: 27372742
Drug: Caffeine (CAF,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF, 6 mg kg(‐1))
Trial: 20558830
Drug: Intensive motor
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive motor training program (n=30) with 3 sessions of physical therapy and a structured home exercise program for 4 weeks after discharge.
Trial: 20558830
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment group (n=32).
Trial: 10430197
Drug: Indomethacin tocolysis
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin tocolysis (50 mg followed by 25 mg 6 hourly for 48 hours)
Trial: 31182047
Drug: Structured skills
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured skills training group (SSTG) based on dialectical behaviour therapy (DBT)
Trial: 17548076
Drug: Metformin 2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 2000 mg/day
Trial: 12817827
Drug: 15 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/day ethanol
Trial: 9277075
Drug: Isoflurane with
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane with thiopental (3‐5 mg/kg for induction), succinylcholine (1‐2 mg/kg for intubation), and vecuronium as a muscle relaxant
Trial: 23287080
Drug: Dobutamine 5
RxNorm normalized name: dobutamine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine 5 μg/kg/min
Trial: 18179368
Drug: 2% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine solution
Trial: 27052531
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid 800 μg/d
Trial: 27052531
Drug: Creatine 3
RxNorm normalized name: Creatine 3200 MG Oral Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine 3 g/d
Trial: 16436724
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg b.i.d. (after 9 doses of 200 mg q.i.d.)
Trial: 16436724
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg b.i.d. (after 9 doses of 400 mg q.i.d.)
Trial: 16436724
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg q.d. (after 5 doses of 800 mg b.i.d.)
Trial: 16436724
Drug: Overall mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall mean exposure of 400 mg b.i.d.
Trial: 16436724
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events leading to premature discontinuation
Trial: 10618936
Drug: Intra-articular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular morphine 2 mg
Trial: 26552352
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) effervescent tablets, daily dose based on weight, for 5 days
Trial: 23299767
Drug: Caffeine supplementation
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine supplementation (6 mg · kg(‐1) body weight, n = 17)
Trial: 2344697
Drug: D-propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-propranolol (120 mg for 5 days)
Trial: 2344697
Drug: L-propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-propranolol (120 mg for 5 days)
Trial: 28274276
Drug: L-citrulline for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-citrulline for 24 weeks
Trial: 24113042
Drug: Ambrisentan 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 2.5 mg or 5 mg once daily for 12 weeks
Trial: 10577447
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg frusemide twice a day
Trial: 1282465
Drug: Loxiglumide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (10 mg kg‐1 h‐1)
Trial: 1752290
Drug: Bile acids
RxNorm normalized name: Conjugated bile acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bile acids (2 g ursodeoxycholic acid plus 2 g chenodeoxycholic acid)
Trial: 7005678
Drug: Prednisolone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (15 to 20 mg per day, maintenance dosage 10 mg per day)
Trial: 24239881
Drug: Sham stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham stimulation + Physical Therapy (PT)
Trial: 22923753
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks
Trial: 9834045
Drug: N-0861 (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-0861 (specific doses administered via bolus and maintenance infusion)
Trial: 2768542
Drug: Haloperidol (4-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (4-16 mg/day)
Trial: 2768542
Drug: Amitriptyline (100-175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (100-175 mg/day)
Trial: 22049162
Drug: Lysine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine intake ranging from 15 to 240 mg · kg(‐1) · d(‐1)
Trial: 11707785
Drug: 3-injection technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-injection technique (group 3N)
Trial: 11707785
Drug: 2-injection technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-injection technique (group 2N)
Trial: 27847634
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4)
Trial: 30946887
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks after 5 monthly doses (2q8)
Trial: 24899557
Drug: One‐to‐one oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One‐to‐one oral instruction strategy combined with an information sheet
Trial: 11872893
Drug: Immunosuppressive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive and anticoagulant therapy
Trial: 10455841
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol 1.5 mg.kg-1
Trial: 2403867
Drug: Intravenous aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous aspirin (60 mg the first day and 20 mg on successive days)
Trial: 2403867
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of isosorbide dinitrate and oral diltiazem
Trial: 2403867
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of aspirin and vasodilators
Trial: 2403867
Drug: Full therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full therapy including heparin and beta-blockers
Trial: 26714411
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Acarbose and Metformin)
Trial: 10598693
Drug: Dorzolamide-timolol combination
RxNorm normalized name: dorzolamide / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide-timolol combination (COSOPT) twice daily
Trial: 30354794
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading 1 μg/kg over 20 min followed by infusion at 0.5 μg/kg/h)
Trial: 14975380
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (50 microg) plus fentanyl (50 microg)
Trial: 22123713
Drug: Dose-dense TC
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense TC with severe anemia (hemoglobin <8.0 g/dL)
Trial: 22123713
Drug: Dose-dense TC
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense TC without severe anemia (hemoglobin >8.0 g/dL)
Trial: 10799160
Drug: Antibiotics (rifampin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (rifampin, doxycycline, erythromycin, metronidazole, clindamycin, amoxicillin, ciprofloxacin) for 18 weeks